Back to results
US 12,605,413 B2Granted
Engineered probiotics for treatment and immunity against viruses
AssigneeUniversity of Cincinnati
InventorsNalinikanth Kotagiri, Nitin S. Kamble
Life of this patent
Estimating the term…
Abstract
The present invention involves an engineered probiotic bacterium comprising a heterologous nucleic acid, where the heterologous nucleic acid comprises a nucleic acid sequence encoding an anti-spike glycoprotein nanobody of a coronavirus. In one embodiment, the bacterium is Escherichia coli Nissle 1917. In another embodiment, the anti-spike glycoprotein nanobody appears on the surface of the probiotic bacteria.
Claims9
An engineered probiotic bacterium comprising a heterologous nucleic acid,
- wherein the heterologous nucleic acid comprises a nucleic acid sequence encoding an anti-spike glycoprotein nanobody of a coronavirus,
- wherein the heterologous nucleic acid is located in a plasmid selected from pNKLab001 having the nucleic acid sequence of SEQ ID NO:
- 5 or SEQ ID NO:
- 6, pNKLab002 having the nucleic acid sequence of SEQ ID NO:
- 7, pNKLab003 having the nucleic acid sequence of SEQ ID NO:
- 8, and pNKLab004 having the nucleic acid sequence of SEQ ID NO:
- 9 or SEQ ID NO:
- 10.
5 more elements
Dependencies are inferred from the claim text.